scholarly journals SEVERE ADVERSE EVENT POST YELLOW FEVER VACCINE IN A PATIENT WITH ANTI-IFN TYPE I AUTOANTIBODIES: A CASE REPORT

2021 ◽  
Author(s):  
Debora Marques Veghini ◽  
Pietra Zava Lorencini ◽  
Ketty Lysie Libardi Lira Machado ◽  
Alexandra Mendes Tonaco Flores Pinto ◽  
Kaicki Teófilo da Silva ◽  
...  
Keyword(s):  
Adverse Event ◽  
Case Report ◽  
Yellow Fever ◽  
Severe Adverse Event ◽  
Yellow Fever Vaccine ◽  
Type I

Corneal Graft Rejection after Yellow Fever Vaccine: A Case Report

2021 ◽  
pp. 1-4
Author(s):  
Roberto Vignapiano ◽  
Lidia Vicchio ◽  
Eleonora Favuzza ◽  
Michela Cennamo ◽  
Rita Mencucci
Keyword(s):  
Case Report ◽  
Yellow Fever ◽  
Graft Rejection ◽  
Corneal Graft ◽  
Yellow Fever Vaccine ◽  
Corneal Graft Rejection

Yellow fever vaccine-associated neurotropic disease (YEL-AND) – A case report

2017 ◽  
Vol 51 (1) ◽  
pp. 101-105 ◽  
Author(s):  
Jolanta Florczak-Wyspiańska ◽  
Ewa Nawotczyńska ◽  
Wojciech Kozubski
Keyword(s):  
Case Report ◽  
Yellow Fever ◽  
Yellow Fever Vaccine

scholarly journals Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination

2022 ◽  
Vol 12 ◽  
Author(s):  
Yair Zlotnik ◽  
Avi Gadoth ◽  
Ibrahim Abu-Salameh ◽  
Anat Horev ◽  
Rosa Novoa ◽  
...  
Keyword(s):  
Adverse Event ◽  
Cognitive Impairment ◽  
Case Report ◽  
Autoimmune Encephalitis ◽  
Neurological Complications ◽  
Severe Adverse Event ◽  
High Dose ◽  
Progressive Dementia ◽  
Vaccination Response ◽  
Muscle Spasms

Anti-leucine rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by cognitive impairment or rapid progressive dementia, psychiatric disorders, faciobrachial dystonic seizures (FBDS) and refractory hyponatremia. Since December 2020, millions of people worldwide have been vaccinated against COVID-19. Several soft neurological symptoms like pain, headache, dizziness, or muscle spasms are common and self-limited adverse effects after receiving the COVID-19 vaccine. However, several major neurological complications, despite the unproven causality, have been reported since the introduction of the COVID-19 vaccine. Herein, we describe a 48 years old man presenting with rapidly progressive cognitive decline and hyponatremia diagnosed with anti LGI1 AE, occurring shortly after the second dose of mRNA COVID -19 vaccine and possibly representing a severe adverse event related to the vaccination. Response to high dose steroid therapy was favorable. As millions of people worldwide are currently receiving COVID-19 vaccinations, this case should serve to increase the awareness for possible rare autoimmune reactions following this novel vaccination in general, and particularly of anti-LGI1 AE.

scholarly journals Yellow fever vaccine-associated viscerotropic disease in a 62-year-old British traveller: a case report

2020 ◽  
Vol 27 (4) ◽  
Author(s):  
Charles D Plumptre ◽  
Richard Harrington ◽  
David Lewis ◽  
Harjit Bains ◽  
Alexander J Mentzer
Keyword(s):  
Case Report ◽  
Yellow Fever ◽  
Yellow Fever Vaccine

scholarly journals Serious adverse event: late neurotropic disease associated with yellow fever vaccine

2020 ◽  
Vol 18 ◽  
Author(s):  
Henrique Souza Barros de Oliveira ◽  
Patricia Padial de Araujo ◽  
Jamile Rafaela Poltronieri de Sousa ◽  
Ana Carolina Gariba Donis ◽  
Deise Moreira ◽  
...  
Keyword(s):  
Adverse Event ◽  
Yellow Fever ◽  
Yellow Fever Vaccine ◽  
Serious Adverse Event

scholarly journals Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection

2019 ◽  
Author(s):  
Ana C. Vicente Santos ◽  
Francisca H. Guedes-da-Silva ◽  
Carlos H. Dumard ◽  
Vivian N. S. Ferreira ◽  
Igor P. S. da Costa ◽  
...  
Keyword(s):  
Viral Load ◽  
Virus Infection ◽  
Yellow Fever ◽  
Zika Virus ◽  
Large Scale ◽  
Yellow Fever Virus ◽  
Yellow Fever Vaccine ◽  
Effective Vaccine ◽  
Type I ◽  
Zika Virus Infection

AbstractZika virus (ZIKV) emerged as an important infectious disease agent in Brazil in 2016. Infection usually leads to mild symptoms but severe congenital neurological disorders and Guillain-Barré syndrome have been reported following ZIKV exposure. The development of an effective vaccine against Zika virus is a public health priority, encouraging the preclinical and clinical studies of different vaccine strategies. Here, we describe the protective effect of an already licensed attenuated yellow fever vaccine (17DD) on type-I interferon receptor knockout mice (A129) and immunocompetent (BALB/c) mice infected with ZIKV. Yellow fever virus vaccination results in robust protection against ZIKV, with decreased mortality in the A129 mice, a reduction in the cerebral viral load in all mice, and weight loss prevention in the BALB/c mice. Despite the limitation of yellow fever (17DD) vaccine to elicit antibody production and neutralizing activity against ZIKV, we found that YF immunization prevented the development of neurological impairment induced by intracerebral virus inoculation in adult. Although we used two vaccine doses in our protocol, a single dose was protective, reducing the cerebral viral load. Different Zika virus vaccine models have been tested; however, our work shows that an efficient and certified vaccine, available for use for several decades, effectively protects mice against Zika virus infection. These findings open the possibility for using an available and inexpensive vaccine to a large-scale immunization in the event of a Zika virus outbreak.

Sign in / Sign up

Export Citation Format

Share Document